ES2294793T3 - Induccion de tolerancia inmunologica a un anticuerpo terapeutico usando variantes de dicho anticuerpo terapeutico. - Google Patents

Induccion de tolerancia inmunologica a un anticuerpo terapeutico usando variantes de dicho anticuerpo terapeutico. Download PDF

Info

Publication number
ES2294793T3
ES2294793T3 ES97905226T ES97905226T ES2294793T3 ES 2294793 T3 ES2294793 T3 ES 2294793T3 ES 97905226 T ES97905226 T ES 97905226T ES 97905226 T ES97905226 T ES 97905226T ES 2294793 T3 ES2294793 T3 ES 2294793T3
Authority
ES
Spain
Prior art keywords
antibody
therapeutic
use according
binding
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97905226T
Other languages
English (en)
Spanish (es)
Inventor
Herman Waldmann
Lisa Kim Gilliland
Masahide Tone
Mark Raymond Frewin
Louise Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Application granted granted Critical
Publication of ES2294793T3 publication Critical patent/ES2294793T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES97905226T 1996-02-20 1997-02-20 Induccion de tolerancia inmunologica a un anticuerpo terapeutico usando variantes de dicho anticuerpo terapeutico. Expired - Lifetime ES2294793T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9603507 1996-02-20
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants

Publications (1)

Publication Number Publication Date
ES2294793T3 true ES2294793T3 (es) 2008-04-01

Family

ID=10789047

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97905226T Expired - Lifetime ES2294793T3 (es) 1996-02-20 1997-02-20 Induccion de tolerancia inmunologica a un anticuerpo terapeutico usando variantes de dicho anticuerpo terapeutico.

Country Status (11)

Country Link
US (2) US20020048578A1 (enExample)
EP (1) EP0970127B1 (enExample)
JP (1) JP4574750B2 (enExample)
AT (1) ATE373016T1 (enExample)
AU (1) AU723366B2 (enExample)
CA (1) CA2246715C (enExample)
DE (1) DE69738138T2 (enExample)
ES (1) ES2294793T3 (enExample)
GB (1) GB9603507D0 (enExample)
NZ (1) NZ331299A (enExample)
WO (1) WO1997031024A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE219517T1 (de) * 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
DE69938054T2 (de) 1998-11-18 2009-02-12 Genentech, Inc., South San Francisco Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
JP4334866B2 (ja) * 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
EP1618891A1 (en) * 2003-03-31 2006-01-25 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory t cell by anti-cd52 antibody and medicinal composition therefor
EP1756278B1 (en) * 2004-05-19 2008-09-17 MediGene Ltd. Method of improving t cell receptors
CA2601400A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
CN101820898B (zh) * 2007-05-16 2013-10-30 中国抗体制药有限公司 互补决定区（CDRs）功能人源化
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
WO2010136598A1 (en) 2009-05-29 2010-12-02 Morphosys Ag A collection and methods for its use
HRP20181811T1 (hr) 2010-11-19 2018-12-28 Morphosys Ag Zbirka sljedova protutijela i njezina upotreba
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013152011A1 (en) * 2012-04-02 2013-10-10 Ab Biosciences, Inc. Novel human control antibodies and uses therefor
CN110078827A (zh) 2012-04-27 2019-08-02 西托姆克斯治疗公司 结合表皮生长因子受体的可活化的抗体其使用方法
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US20160120158A1 (en) * 2014-11-03 2016-05-05 The Johns Hopkins University Compositions and methods for the study and treatment of acute kidney injury
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP3962926A4 (en) 2019-04-30 2022-11-23 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0610447B1 (en) * 1991-10-15 1998-12-16 Btg International Limited CDw52 - SPECIFIC ANTIBODY FOR TREATMENT OF T-CELL MEDIATED INFLAMMATION OF THE JOINTS
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
EP0970127B1 (en) 2007-09-12
US20020048578A1 (en) 2002-04-25
GB9603507D0 (en) 1996-04-17
AU723366B2 (en) 2000-08-24
ATE373016T1 (de) 2007-09-15
JP2000506723A (ja) 2000-06-06
US20060018898A1 (en) 2006-01-26
NZ331299A (en) 2000-05-26
WO1997031024A1 (en) 1997-08-28
CA2246715C (en) 2008-08-05
DE69738138D1 (de) 2007-10-25
US8440190B2 (en) 2013-05-14
EP0970127A1 (en) 2000-01-12
CA2246715A1 (en) 1997-08-28
JP4574750B2 (ja) 2010-11-04
DE69738138T2 (de) 2008-06-05
AU1885197A (en) 1997-09-10

Similar Documents

Publication Publication Date Title
EP0970127B1 (en) Induction of immunological tolerance to a therapeutic antibody using variants of the said therapeutic antibody
ES2199216T3 (es) Produccion de anticuerpos.
ES2296839T3 (es) Variantes de inmunoglobulinas para receptores fc-epsilon especificos.
US7524498B2 (en) Human immunomodulatory monoclonal antibodies for the treatment of cancer
JP4214173B2 (ja) 寛容原性融合タンパク質による寛容性の誘発
US6294654B1 (en) Modified immunoglobulin molecule incorporating an antigen in a non-CDR loop region
ES2368387T5 (es) Anticuerpos terapéuticos y que inducen tolerancia
US8187600B2 (en) Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses
ES2277336T3 (es) Antagonistas de il-5 recombinantes utiles en el tratamiento de enfermadades mediadas por il-5.
JPH08511421A (ja) 人化抗体
ES2307301T3 (es) ANTICUERPO LO-CD2a Y USOS DEL MISMO PARA INHIBIR LA ACTIVACION Y PROLIFERACION DE CELULAS T.
BG62656B1 (bg) Рекомбинантни антитела за хуманната медицина
HU228159B1 (en) Antibodies to human il-1beta
US7635476B2 (en) Anti-hepatitis a virus antibodies
ES2234099T3 (es) Anticuerpos monoclanales humanizados anti-alfa beta 3.
AU2002225230A1 (en) Polypeptides capable of binding to CD64 and comprising one or more heterologous T cell epitopes, and their uses
Zanetti et al. Idiotype Vaccines by Antibody Engineering: Structural and Functional Considerations
Zanetti et al. Idiotype Vaccines by Antibody Engineering: Structural and Functional
RO116809B1 (ro) Anticorp recombinant, monoclonal, compozitie farmaceutica si metoda de tratament cu aceasta